GLP-1s Tied to Weight Loss in Real-World Rheumatologic Care
The study examined the use of semaglutide and tirzepatide among patients with rheumatic and musculoskeletal diseases, finding that both treatments led to significant weight loss over one year. Tirzepatide users experienced greater weight loss compared to those using semaglutide, particularly among individuals without diabetes. The research highlights the varying efficacy of GLP-1 receptor agonists in real-world settings.
- ▪The use of semaglutide and tirzepatide among patients with RMDs increased from 0.1% in 2018 to 6.8% in 2024.
- ▪Tirzepatide users lost an average of 8.2% of body weight at 12 months, compared to 5.8% for semaglutide users.
- ▪Patients without diabetes lost 1.8% more weight than those with diabetes.
- ▪Tirzepatide users were nearly 50% more likely to lose at least 5% of body weight than semaglutide users.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:The use of semaglutide and tirzepatide increased over time among patients with rheumatic and musculoskeletal diseases (RMDs). Both treatments were associated with meaningful weight loss at 1 year, with greater reductions seen in tirzepatide users and in people without diabetes.METHODOLOGY:Researchers analyzed data from a rheumatology registry to describe initiation patterns of semaglutide and tirzepatide in patients with RMDs and to identify factors linked to weight loss.They included 60,198 adults with RMDs treated in US rheumatology practices between 2018 and 2024 (mean age, 57.0 years; 80.5% women).
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
